Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development
New York City, United States, July 7th, 2026, FinanceWire
Octozi, an artificial intelligence company that automates clinical development workflows for pharmaceutical sponsors, has raised $3 million in seed funding. The round was led by Surface Ventures, with participation from Remarkable Ventures, and follows a prior investment from the venture arm of Debiopharm, a Swiss pharmaceutical company.
Clinical trials generate substantial volumes of data that must be cleaned, reconciled, and reviewed before a new treatment can gain a drug approval from regulators. Much of this work is performed manually by data managers, medical monitors, and safety teams, which adds time and cost to drug development.
Octozi’s platform integrates with existing clinical systems and uses a human-in-the-loop design ...
